Clinical Trials Browser

Phase NA × Neoplasm, Residual × daratumumab × Clear all

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Phase NA Recruiting

Multiple Myeloma, Neoplasm, Residual